Evotec

PharmaTimes | September 24, 2019

Evotec has entered into a strategic, multi-year drug discovery collaboration with Takeda, which aims to establish at least five drug discovery programmes for the latter to develop. Under the plans, Evotec will utilise its drug discovery platform to validate therapeutic hypotheses and advance small molecule programmes across Takeda's core areas of interest: oncology, gastroenterology, neuroscience and rare diseases. Takeda has options to assume responsibility at lead series and upon Evotec de...

Pharmaceutical Technology | September 25, 2019

German drug discovery company Evotec has announced it has signed a multi-year drug discovery collaboration with Japanese pharma company Takeda. Evotec will leverage its technology platform to establish at least five drug discovery programmes, which Takeda will advance into clinical development. The focus of these programmes will be in Takeda’s core therapeutic areas – oncology, gastroenterology, neuroscience and rare diseases. The German company’s discovery platform is based up...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...